Three-in-one TB drug approved. Clearinghouse, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5023. NLM AIDSLINE Important note: Information in this article was accurate in 1995. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Three-in-one TB drug approved. Clearinghouse, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5023.

Posit Aware. 1995 May/Jun;:5. Unique Identifier : AIDSLINE AIDS/95700394

Abstract: Marrion Merrell Dow can now market Rifater, a combination of three drugs already approved to treat tuberculosis (TB), according to the Food and Drug Administration (FDA). Rifater, which consists of rifampin, isoniazid, and pyrazinamide, was developed to assist patients in complying with their dosage schedules. Patients will take rifater for two months; therapy with rifampin and isoniazid is continued for an additional four months.
Keywords: Drug Approval Drug Therapy, Combination Human Isoniazid/ADMINISTRATION & DOSAGE/*THERAPEUTIC USE Pyrazinamide/ADMINISTRATION & DOSAGE/*THERAPEUTIC USE Rifampin/ADMINISTRATION & DOSAGE/*THERAPEUTIC USE Tuberculosis/*DRUG THERAPY United States Food and Drug Administration NEWSLETTER ARTICLEKWDdrugapprovaldrugtherapy,combinationhumanisoniazid/administration&dosage/KWDtherapeuticusepyrazinamide/administration&dosage/KWDtherapeuticuserifampin/administration&dosage/KWDtherapeuticusetuberculosis/KWDdrugtherapyunitedstatesfoodanddrugadministrationnewsletterarticle
951230
M95C3200

Copyright © 1995 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1995. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1995. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .